DEAR DR. ROACH: I recently brought myself to the hospital because my electrocardiogram (EKG) result showed “possible ischemia ...

A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said ...

In the ABYSS trial, researchers found that interrupting a beta-blocker in patients after a myocardial infarction resulted in ...

Personality traits can influence cardiovascular disease (CVD) risk with type 2 diabetes mellitus (T2DM), according to a study ...

Young patients with myocardial infarction (MI) and fewer traditional risk factors often have greater exposure to urban noise, ...

Percutaneous coronary intervention (PCI) has proven lifesaving: Morbidity and mortality outcomes are significantly improved ...

Several firms are bringing high-sensitivity cardiac troponin testing into the ER, although doctors are not yet certain how ...

JPI-289 is under clinical development by Jeil Pharmaceutical and currently in Phase II for Myocardial Infarction.

In a large meta-analysis, complete revascularisation reduced cardiovascular events compared with culprit-only revascularisation in older patients with a myocardial infarction and multivessel disease ...

Background In acute heart failure (HF), reduced cardiac output, vasoconstriction and congestion may damage the intestinal ...

BACKGROUND: Cardiac troponin (cTn) is key in diagnosing myocardial infarction (MI). After MI, the clinically observed half-life of cTn has been reported to be 7 to 20 hours, but this estimate reflects ...

Acute myocardial infarction (AMI) remains a major cause of death, with limited understanding of its early risk stratification. While late-stage AMI has recognized associations with gut microbiome ...